Physician profile
Mark Robert Kahn
NPI 1134443112
$3,920.41
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $309 · 2021: $664 · 2022: $688 · 2023: $702 · 2024: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $839.77 | 2019-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.48 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $393.69 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $359.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $321.95 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $316.58 | 2019-2024 | Eliquis |
| Pfizer INC. | $315.74 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $174.78 | 2019-2023 | Xarelto |
| Amgen INC. | $113.42 | 2019 | |
| Novo Nordisk INC | $89.64 | 2019 | |
| Abbott Laboratories | $68.75 | 2019-2024 | Aveir |
| Amarin Pharma, INC. | $57.19 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $44.81 | 2019 | |
| Eisai INC. | $38.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.96 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $29.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.49 | 2023 | Lifevest |
| Arbor Pharmaceuticals, INC. | $19.95 | 2021 | |
| Lilly USA, LLC | $17.74 | 2019 | |
| Medicomp INC | $17.04 | 2022 | |
| Infobionic, INC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.